Remove Arrhythmia Remove Innovation Remove Patient Care
article thumbnail

HRS 2024: Innovation Meets Reality

DAIC

Innovation in medical technology exists to improve patient outcomes, increase surgical efficiency and enhance patient safety. Infrequently, we see medical technology innovation of a paradigmatic nature that changes the way physicians approach disease states and dramatically improve results. So, again, innovation is great.

article thumbnail

Heart Rhythm Society’s HRX 2024 to Draw Cardiovascular Innovators to Atlanta

DAIC

The Heart Rhythm Society (HRS) is preparing for HRX 2024, the third annual event of its kind, which will be held from September 5-7, 2024, in Atlanta, GA, gathering cardiovascular health innovators together to explore discoveries and advance partnerships between medicine and technology. On Thursday, Sept.

article thumbnail

Penn Presbyterian Medical Center Becomes First Hospital in the Northeast to Adopt Advanced Robotic Technology for Heart Treatment

DAIC

milla1cf Thu, 05/30/2024 - 10:31 May 30, 2024 — Stereotaxis , a pioneer in surgical robotics for minimally invasive endovascular intervention, announced the successful treatment of the first heart rhythm patients by Penn Presbyterian Medical Center (PPMC) utilizing the advanced Genesis Robotic Magnetic Navigation System.

article thumbnail

Biosense Webster Begins Enrollment of Pivotal Trial Evaluating the Laminar Left Atrial Appendage Elimination Device?

DAIC

a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTechi , announced the commencement of patient cases with the investigational Laminar Left Atrial Appendage Elimination (LAAX) System as part of its pivotal investigational device exemption (IDE) study. The acquisition of Laminar, Inc.

article thumbnail

Volta Medical Enters into Joint Development Agreement with GE HealthCare to Support Electrophysiologists Treating Atrial Fibrillation

DAIC

Volta Medical has announced it has entered into a Joint Development Agreement with GE Healthcare to enhance arrhythmia procedures with artificial intelligence (AI)-driven electrophysiology technologies. 1 Approximately 33 million patients worldwide are living with AFib. The company has obtained U.S.

article thumbnail

Spotlight on Advancements in Mitral Valve Repair, Research

DAIC

The Smidt Heart Institute recently received CAROL Act funding to study the connection between ventricular arrhythmias—abnormal heartbeats that start in the heart’s two lower chambers—and an elevated risk of sudden cardiac death in patients with mitral valve disease. Patients come to us from all over the U.S.

article thumbnail

Biosense Webster Study Supports Low and Zero Fluoroscopy Workflow as Safe, Effective Alternative to Conventional Catheter Ablation

DAIC

a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTechi , revealed findings from a company-funded study of real-world data. AFib is the most common type of cardiac arrhythmia and affects more than 6 million people in the United States and nearly 38 million people worldwide.2,3

Ablation 105